Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder
Adam R Aron1, Jonathon H Dowson, Barbara J Sahakian
1Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom.
Background:
Response inhibition is an executive function that requires voluntary control over responses when there is a change of context. The right inferior frontal cortex is necessary for response inhibition, and a deficit in right frontostriatal circuitry might underlie attention-deficit/hyperactivity disorder (ADHD). Many studies of childhood ADHD have demonstrated impaired response inhibition and its amelioration by methylphenidate (MPH). The current study tested response inhibition and the effect of MPH in adult ADHD.
Methods:
Response inhibition was assessed with the "tracking" stop-signal test in 13 adults with a diagnosis of ADHD, both while taking and while not taking medication, and 13 healthy, unmedicated, age- and intelligence quotient-matched control subjects.
Results:
Stop-signal reaction time was significantly slower in unmedicated adults with ADHD relative to healthy control subjects, and this deficit was significantly ameliorated by medication.
Conclusions:
Adult ADHD patients had a response inhibition profile similar to that produced by lesions to the right inferior frontal cortex, which was remedied by stimulant medication.
More Related Videos
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...


